Tagged with BMS,

Romania With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the charge against cancer. The combined entity is expected to rise in the global biopharma rankings, complete with a fresh new…

Global The world’s bestselling treatments for 2019 by sales in USD billions. AbbVie’s Humira is out in front with USD 19.7 billion in sales, followed by Bristol Myers Squibb’s Eliquis, and Merck & Co. (MSD globally)’s Keytruda.   Made with Visme Infographic Maker

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Romania Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has become Romanian market leader in immuno-oncology by launching new indications and therapy lines for its products in the country. He…

Sweden Though far from the largest pharma market in Europe, Sweden nevertheless holds strategic importance for global pharma; from the country’s attitude to public health to its sophisticated digital framework, comprehensive patient registries and innovative spirit. Here, four pharma country managers hailing from outside Sweden’s borders give their first impressions of…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

Puerto Rico Leobardo Hidalgo, who lived in Puerto Rico as a child, recently came back to the island to head commercial operations at the local BMS affiliate, which has been performing remarkably well. He highlights a portfolio of transformational medicines matched with the local team’s patient-centric approach and knowledge of the ecosystem…

Sweden Iddo Leshem, general manager Nordics at Bristol-Myers Squibb (BMS), talks about the uniqueness of Sweden’s collaborative culture and shatters some of the entrenched stereotypes about the country. He then breaks down the drivers behind the outstanding performance of the affiliate and emphasizes the important role Sweden plays in the development…

Thailand PharmaBoardroom last reported on Thailand in 2015, meeting country managers from across the healthcare and life sciences value chain. Here, we chart some of their career progressions since then.   Sticking with Servier Guillaume Drianno Guillaume Drianno was Thailand country manager for French firm Servier between 2013 and 2017. Prior…

Sweden The top 50 most sold drugs in Sweden for 2018. AbbVie’s Humira takes the top spot for the second year running, followed by Gilead’s Epclusa and BMS and Pfizer’s Eliquis.   Made with Visme Infographic Maker  

Turkey Ece Kaşıkçı, General Manager, Bristol-Myers Squibb (BMS) Turkey, outlines how BMS’ groundbreaking immuno-oncology therapy has proudly become the first product of its kind to be registered and reimbursed in the country. She also highlights the company’s collaborative approach to reach this remarkable milestone. Ece also discusses her vision for BMS…

Brazil Gaetano Crupi, president and general manager of BMS in Brazil, leverages his long-standing experience at the head of prestigious pharmaceutical companies’ affiliates to provide an insightful overview of the key success factors to consider in the Brazilian market. He also documents BMS’ commitment to being a frontrunner in the medical,…